Source: Pharmacy Times articles
The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
Read More
Recent Content
- Introduction and Overview of Multiple Myeloma
- Evaluation and Diagnosis of Multiple Myeloma
- Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy
- Spinal intradural lesion as manifestation of multiple myeloma: Illustrative case and systematic review of literature
- Comparison of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI for Initial Staging of Multiple Myeloma: A Systematic Review and Meta-analysis
- Incidence and prevalence of light chain amyloidosis in the United States in 2019–2021 using Optum EHR data
- Interleukin-6 is a highly prognostic biomarker for POEMS syndrome
- Targeting proteostasis in multiple myeloma through inhibition of LTK
- IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma
- EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma